Coming October 29: SITC releases its late-breaking abstract titles. We’ll add their presenting authors’ institutions to this guide once they’re out.

HanchorBio at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

HanchorBio brings 4 presentations to SITC 2026 in Phoenix. Its program centres on drugs built around SIRPα that target the CD47 pathway in innate immune cells, some combined with other checkpoint targets. A concrete result is lasting responses, including complete ones, with HCB101 in recurrent or metastatic head and neck cancer.

Organization	SITC 2026 Attendance
H HanchorBio Taipei, Taiwan
	Poster Fri Nov 6 12:15–1:45pm 5:30–7pm HCB301, a trispecific SIRPα–PD-L1–TGFβ fusion protein, enables multi-axis immune reprogramming in advanced malignancies Exhibition Halls 4-6 · Poster 565 New agents · Clinical Poster Fri Nov 6 12:15–1:45pm 5:30–7pm HCB303 extends SIRPα-based trispecific engineering to TIGIT/CD155-driven adaptive checkpoint resistance Exhibition Halls 4-6 · Poster 399 New agents Poster Sat Nov 7 12:30–1:30pm 6:40–8:10pm Durable response and complete response signal support HCB101 CD47–SIRPα blockade as a myeloid-directed strategy in R/M HNSCC Exhibition Halls 4-6 · Poster 526 New agents · Clinical Poster Sat Nov 7 12:30–1:30pm 6:40–8:10pm Solving CD47–SIRPα backbone usability: HCB101 enables regimen-ready innate immune combinations and platform extension Exhibition Halls 4-6 · Poster 578 New agents

Organization

SITC 2026 Attendance

HanchorBio

Taipei, Taiwan

Poster

Fri Nov 6
12:15–1:45pm
5:30–7pm

HCB301, a trispecific SIRPα–PD-L1–TGFβ fusion protein, enables multi-axis immune reprogramming in advanced malignancies

Exhibition Halls 4-6 · Poster 565

New agents · Clinical

Poster

Fri Nov 6
12:15–1:45pm
5:30–7pm

HCB303 extends SIRPα-based trispecific engineering to TIGIT/CD155-driven adaptive checkpoint resistance